MedPath

Exploratory study 2 of FYX-051 in Patients with Hyperuricemia (with or without Gout)

Phase 2
Conditions
Hyperuricemia and Gout
Registration Number
JPRN-jRCT2080221279
Lead Sponsor
Fuji Yakuhin Co., Ltd.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Sex
All
Target Recruitment
Not specified
Inclusion Criteria

Patients with hyperuricemia with the following serum urate level:
- Serum urate level of >= 8.0mg/d

Exclusion Criteria

Patients with gouty arthritis within two weeks before start of study treatment
Patients with secondary hyperuricemia
Patients with, or a history of, clinically significant cardiac, hematologic and hepatic disease

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Efficacy and Safety
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath